Primary aldosteronism
Conditions
Interventions
Primary aldosteronism individuals:Use the drug of finerenone
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Clearly diagnosed with primary aldosteronism. 2.No administration of spironolactone, eplerenone, amiloride, or triamterene in the month prior to enrollment. 3.No use of antihypertensive medications other than calcium channel blockers and a-receptor blockers in the two weeks prior to enrollment.
Exclusion criteria
Exclusion criteria: Children/Minors; Adults with cognitive impairments or health conditions that render them incapable of providing informed consent; Patients in the terminal stage of illness; Prisoners or individuals subjected to forced labor; Pregnant or breastfeeding individuals; Blood potassium levels > 5.0 mmol/L; Coexisting Addison's disease; Individuals allergic to any component of norethisterone; Concurrent use of potent CYP3A4 inhibitors (itraconazole, ketoconazole, ritonavir, nelfinavir, cobicistat, clarithromycin, telithromycin, nefazodone) Estimated glomerular filtration rate (eGFR) < 25 ml/min/1.73m^2 Within 90 days of myocarditis, acute myocardial infarction, coronary artery revascularization, stroke, or transient ischemic attack
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum potassium; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure;24h Urine potassium; | — |
Countries
China
Contacts
Public ContactMing Liu
Tianjin Medical University General Hospital
Outcome results
None listed